Bladder cancer represents one of the most prevalent malignant neoplasms of the urinary
tract. In the Asian context, it represents the eighth most common cancer in males. In 2022 …

Metastatic urothelial carcinoma (muC) has historically had few effective therapeutic options.
Recently, immune checkpoint inhibitors (ICIs), were introduced as therapeutic options for …

Cisplatin-based chemotherapy has long been the standard first-line (1L) treatment for
metastatic urothelial carcinoma (mUC). However, up to 50% of patients with mUC may be …

Background Programmed death-ligand 1 (PD-L1) expression is abundant not only in
malignant cells but also in infiltrating cells within the tumor microenvironment (TME) of …

Simple Summary Antibody–drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs)
are two promising therapeutic modalities against many types of cancers. However, many …

Gastric cancer is a malignant disease with a poor prognosis and few therapeutic options
once it has advanced. Immunotherapy using ICIs has emerged as a viable therapeutic …

Background: Bladder cancer (BLCA) is a prevalent and aggressive cancer associated with
high mortality and poor prognosis. Currently, studies on the role of disulfidptosis-related long …

Background and Objective A standard of care for muscle-invasive bladder cancer (MIBC) is
cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) …

Background Immune checkpoint inhibitors (ICIs) are promising in metastatic urothelial
cancer (mUC). However, the clinical benefits remain limited despite using biomarkers like …